Interview by Mary Caffrey

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of the election.

An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.

An interview with Mark Lanasa, MD, PhD, BeiGene senior vice president and chief medical officer for solid tumors, conducted at ASCO 2024.

Ishwaria Subbiah, MD, of SCRI Oncology Partners, discusses new findings presented at ASCO 2024. This interview will appear in the annual ASCO recap issue of Evidence-Based Oncology.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

This interview with the lead investigator of the MIRASOL trial, which was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, will appear with coverage of ASCO in the upcoming issue of Evidence-Based Oncology.

Final overall survival data were presented at the European Lung Cancer Congress in Copenhagen, Denmark.

CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”

Evidence-Based Oncology™ (EBO) spoke with TailorMed's Ian Manners about the financial assistance and consumer protection landscape, and what the cost of cancer care means to patient experience and outcomes.

Evidence-Based Oncology (EBO) spoke with Len Lichtenfeld, MD, the chief medical officer for Jasper Health and a board member with CancerCare.

Evidence-Based Oncology™️ spoke with Lyons about the creation of this real-world data set and the pros and cons of different treatments for MDS.

An interview with Joseph R. Mikhael, MD, MEd, on findings from a Quality Improvement initiative presented during the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, in Phoenix, Arizona.